Gritstone bio Stock Forecast, Price & News

Gritstone bio (NASDAQ:GRTS) Frequently Asked Questions

Is Gritstone bio a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Gritstone bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRTS, but not buy additional shares or sell existing shares.
View analyst ratings for Gritstone bio or view top-rated stocks.

How has Gritstone bio's stock price been impacted by COVID-19 (Coronavirus)?

Gritstone bio's stock was trading at $6.67 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GRTS shares have increased by 66.7% and is now trading at $11.12.
View which stocks have been most impacted by COVID-19.

Are investors shorting Gritstone bio?

Gritstone bio saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 2,080,000 shares, an increase of 18.9% from the October 14th total of 1,750,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the days-to-cover ratio is currently 2.0 days.
View Gritstone bio's Short Interest.

When is Gritstone bio's next earnings date?

Gritstone bio is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Gritstone bio.

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.52) by $0.16. Gritstone bio had a negative net margin of 155.88% and a negative trailing twelve-month return on equity of 38.51%.
View Gritstone bio's earnings history.

What price target have analysts set for GRTS?

3 brokerages have issued twelve-month target prices for Gritstone bio's stock. Their forecasts range from $8.00 to $35.00. On average, they expect Gritstone bio's stock price to reach $22.33 in the next twelve months. This suggests a possible upside of 100.8% from the stock's current price.
View analysts' price targets for Gritstone bio or view top-rated stocks among Wall Street analysts.

Who are Gritstone bio's key executives?

Gritstone bio's management team includes the following people:

• Andrew R. Allen, President, Chief Executive Officer & Director
• Erin E. Jones, Chief Operating Officer (LinkedIn Profile)
• Vassiliki Celia Economides, Chief Financial Officer & Executive Vice President
• Karin Jooss, Head-Research & Development
• Raphaël Rousseau, Chief Medical Officer & Executive Vice President

What is Andrew Allen's approval rating as Gritstone bio's CEO?

1 employees have rated Gritstone bio CEO Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among Gritstone bio's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Gritstone bio's key competitors?

Some companies that are related to Gritstone bio include ImmunityBio (IBRX), Iovance Biotherapeutics (IOVA), Instil Bio (TIL), Kymera Therapeutics (KYMR), Allogene Therapeutics (ALLO), Ginkgo Bioworks (DNA), Editas Medicine (EDIT), BioCryst Pharmaceuticals (BCRX), Revolution Medicines (RVMD), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), Krystal Biotech (KRYS), C4 Therapeutics (CCCC), Vericel (VCEL) and Alector (ALEC).
View all of GRTS's competitors.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

When did Gritstone bio IPO?

(GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

What is Gritstone bio's stock symbol?

Gritstone bio trades on the NASDAQ under the ticker symbol "GRTS."

Who are Gritstone bio's major shareholders?

Gritstone bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include EcoR1 Capital LLC (8.18%), Versant Venture Management LLC (8.10%), BlackRock Inc. (6.42%), BVF Inc. IL (3.09%), Geode Capital Management LLC (1.43%) and Invesco Ltd. (0.84%). Company insiders that own Gritstone bio stock include Erin Jones and Raphael Rousseau.
View institutional ownership trends for Gritstone bio.

Which institutional investors are selling Gritstone bio stock?

GRTS stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Versant Venture Management LLC, BVF Inc. IL, Ensign Peak Advisors Inc, Two Sigma Advisers LP, Russell Investments Group Ltd., Marshall Wace LLP, and Dimensional Fund Advisors LP. Company insiders that have sold Gritstone bio company stock in the last year include Erin Jones, and Raphael Rousseau.
View insider buying and selling activity for Gritstone bio or view top insider-selling stocks.

Which institutional investors are buying Gritstone bio stock?

GRTS stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, BlackRock Inc., Invesco Ltd., Geode Capital Management LLC, Jane Street Group LLC, Citadel Advisors LLC, UBS Group AG, and DG Capital Management LLC.
View insider buying and selling activity for Gritstone bio or or view top insider-buying stocks.

How do I buy shares of Gritstone bio?

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gritstone bio's stock price today?

One share of GRTS stock can currently be purchased for approximately $11.12.

How much money does Gritstone bio make?

Gritstone bio has a market capitalization of $756.05 million and generates $4.04 million in revenue each year. The company earns $-105.31 million in net income (profit) each year or ($1.28) on an earnings per share basis.

How many employees does Gritstone bio have?

Gritstone bio employs 169 workers across the globe.

What is Gritstone bio's official website?

The official website for Gritstone bio is www.gritstoneoncology.com.

Where are Gritstone bio's headquarters?

Gritstone bio is headquartered at 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608.

How can I contact Gritstone bio?

Gritstone bio's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at (510) 871-6100 or via email at [email protected].